Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.51 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573036 | 0.81 | SOAT2 (0.51) | SOAT2ACAT1SOAT1SLC6A4SLC6A3 | |
| SCHEMBL28093470 | 0.78 | SOAT2 (0.60) | SOAT2ACAT1SOAT1 | |
| Hydrochloric Acid SCHEMBL28177156 | 0.77 | SOAT2 (0.59) | SOAT2ACAT1SOAT1 | |
| SCHEMBL7508542 | 0.75 | DPP4 (0.58) | SLC6A4SLC6A3SLC6A2 | |
| Nevanimibe SCHEMBL1119314 | 0.69 | SOAT1 (1.00) | SOAT2ACAT1SOAT1 | |
| SCHEMBL11161896 | 0.68 | ALDH1A1 (0.56) | SLC6A4SLC6A3SLC6A2HDAC3HDAC1 | |
| SCHEMBL1119316 | 0.68 | SOAT2 (0.69) | SOAT2ACAT1SOAT1 | |
| SCHEMBL2386424 | 0.67 | LMNA (0.49) | — | |
| SCHEMBL3306927 | 0.67 | ALDH1A1 (0.50) | HDAC3HDAC1HDAC7HDAC2HDAC8 | |
| SCHEMBL7862580 | 0.66 | ALDH1A1 (0.48) | SOAT2ACAT1SOAT1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| CN-1370526-A | Treating method of nuclear factor-KB mediated diseases and dysfuction | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | SOAT2 324/4885ACAT1 231/4885SOAT1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.